A new study suggests that Resmetirom may do more than treat fatty liver disease — it could also help stop liver cancer from developing. Resmetirom, a drug approved by the U.S. Food and Drug Administration (FDA) to treat metabolic dysfunction associated fatty liver disease (MAFLD), may offer benefits beyond reducing liver fat and fibrosis, according […]This is a curated summary.